Test-Specific Blocking Antibodies for Immunoassay Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional immunoassays face challenges in accurately analyzing samples due to interference from heterophilic antibodies and rheumatoid factors, despite the use of conventional blocking reagents, leading to false-positive or false-negative results.
Innovation Solution
Employ a blocking antibody with an amino acid sequence identical to the analytical antibody, except for one to three altered residues, significantly reducing its antigen-binding capacity to effectively intercept and block interfering antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional blocking reagents (mixtures of random non-specific antibodies) are used, then general blocking of interfering antibodies is achieved, but interference from certain samples (e.g., HAMA antibodies) remains insufficiently blocked
Solution Approach 1:
The patent creates a blocking antibody that is a modified copy of the analytical antibody, with identical amino acid sequence except for one to three altered residues. This copy has greatly reduced antigen-binding capacity but retains the ability to bind interfering antibodies, providing sample-specific blocking where conventional random antibody mixtures fail.
2Object-affected harmful factors
If irrelevant analytical antibodies are used as blocking agents, then interfering antibodies are occupied and prevented from binding to the analytical antibody, but the blocking effect is insufficient for highly specific interfering antibodies
Solution Approach 1:
The blocking antibody has localized modifications (one to three altered amino acid residues) in specific regions that reduce its antigen-binding capacity while preserving its ability to bind interfering antibodies. This creates a antibody with differentiated functional properties - weak analytical function but strong blocking function.
3Reliability
If the amino acid sequence of the blocking antibody is made identical to the analytical antibody except for one to three altered residues, then the blocking antibody effectively intercepts interfering antibodies, but its antigen-binding capacity must be greatly reduced to avoid competition
Solution Approach 1:
The patent modifies specific parameters of the antibody structure (one to three amino acid residues) to fundamentally change its functional properties. The altered residues reduce the antigen-binding capacity by a factor of at least 100-fold while maintaining the ability to bind interfering antibodies, achieving a parameter transformation that enables the blocking function without analytical interference.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified blocking antibody effectively reduces interference by up to 15%, enhancing the reliability of immunoassay results by preventing binding of interfering antibodies to the analytical antibody.
Implementation Method 1
a blocking antibody, derived from the analytical antibody... which binds to interfering antibodies contained in the sample
Data Source
Figure 1a~1b
Figure 2
AI summary
The present invention is in the field of immunoassays for in vitro diagnostic applications and relates to the use of a test-specific blocking antibody to reduce interference caused by heterophilic antibodies or rheumatoid factors.